Alis Biosciences launches fund to free over $30 billion of capital for biotechs

21 April 2025

London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in listed, development-stage biotech companies, has formally launched.

Founded by highly experienced industry and investment executives, Alis' goal is to protect public shareholders' funds while still supporting company management and boards.

According to Alis, currently, there are nearly 300 listed, development stage life sciences and biotech companies worldwide that have experienced clinical, regulatory or commercial setbacks. These have trapped capital worth over $30 billion on their balance sheets, with market caps ranging from $5 million to $100 million and cash reserves ranging from $10 million to $400 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK